Tests AZD0120 cell therapy in adults with systemic sclerosis, myositis or rheumatoid arthritis

Trial details

Who runs it

AstraZeneca

Trial code

NCT07295847

Record updated

10 November 2026

Original description

This trial is a Phase 1b/2, open-label, multi-center, clinical study of AZD0120, a BCMA/CD19 dual targeting CAR+ T-cell therapy, to evaluate the safety and tolerability in adult participants with systemic sclerosis (SSc), idiopathic inflammatory myopathies (IIM), or difficult-to-treat rheumatoid arthritis (D2T RA).Read full original descriptionShow less

A Phase 1b/2, Open-label, Multi-cohort Study of AZD0120, an Autologous CD19/BCMA Targeting Chimeric Antigen Receptor T-cell, in Adults With Autoimmune Diseases

This trial is a Phase 1b/2, open-label, multi-center, clinical study of AZD0120, a BCMA/CD19 dual targeting CAR+ T-cell therapy, to evaluate the safety and tolerability in adult participants with systemic sclerosis (SSc), idiopathic inflammatory myopathies (IIM), or difficult-to-treat rheumatoid arthritis (D2T RA).

Inclusion: Capable of giving signed informed consent; Adequate physiological function and reserve at screening; Able to comply with recommended medication washout period; Participants who are suitable for the study as determined by medical evaluation and at the discretion of the investigator; Willingness to remain on/start appropriate, highly effective methods of birth control or other acceptable criteria; Particpant musy be 18-years-old to ≤ 75-years-old inclusive at the time of signing the informed consent; Others as described in Clinical Study Protocol.

Exclusion: Any prior CAR T exposure; Received a bone marrow or solid organ transplant at any time or on an active transplant waiting list; Received any investigational drug within ≥ 5 half-lives or 4 weeks, whichever is longer, prior to screening; Other concurrent autoimmune or autoinflammatory disease. Certain autoimmune/autoinflammatory diseases may be included after discussion with the medical monitor; Evidence of clinically significant bleeding or active bleeding conditions within 90 days before screening; Active viral, bacterial, or fungal infection, or any ongoing infection that requires systemic antimicrobial therapy in the 4 weeks prior to screening; Active syphilis, positive for Treponema pallidum antibody; Vaccinated with live, attenuated vaccine within 4 weeks prior to apheresis or lymphodepletion; - Major surgery within 8 weeks prior to apheresis or has surgery planned during the study; Pregnant, breastfeeding, or planning to become pregnant while enrolled in this study or within 1 year after receiving study treatment (whichever is later); Plans to father a child while enrolled in this study or within 1 year after receiving study treatment (whichever is later); Has certain cardiac conditions that could make it unsafe or unsuitable to take part in the study; Uncontrolled hypertension (> 160/100 mmHg) or symptomatic hypertension; Any central nervous system disease that may impact participants safety in the investigator's opinion; History of malignancy or ongoing treatment for prior malignancy. Certain malignancies may be excepted; Seropositive for HIV or HTLV; Active viral hepatitis are excluded; Known life threatening allergies, hypersensitivity, or intolerance to AZD0120 or its excipients, including dimethyl sulfoxide; Contraindications or hypersensitivity to fludarabine and cyclophosphamide; Any issue that would impair the ability of the participant to receive or tolerate the planned treatment at the investigational site, to provide informed consent or any condition in the opinion of the investigator, participation would not be in the best interest of the participant; Unable or unwilling to remain within proximity (2 hours travel time) of the administering investigational site post discharge for the first 28 days post AZD0120 administration; Requirement for supplemental oxygen at rest (except at night for sleep apnea) or mechanical ventilation; Known genetic inborn error of immunity and/or primary immunodeficiency; Not up-to-date on vaccinations per local/national health authority or institutional guidelines for immune-compromised individuals; Other protocol-defined eligibility criteria may apply.

ClinicalTrials.gov NCT07295847